SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : New Brunswick Scientific Co., Inc. (NBSC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (3)5/31/2000 12:43:00 AM
From: tommysdad  Read Replies (1) of 724
 
Diogenesis was semi-profiled in May 15 "Genetic Engineering News", page 10 (online at www.genwire.com), including comments from Arthur Blume. One can easily see how translation of the patent could be difficult, since this Reader's Digest version is tough to follow. Bottom line is they claim to have a very round-about and involved way of finding small-molecule ligands for protein-protein targets. The "orally available" tickler is strictly this small-molecule (vs. protein) angle -- they don't have some secret way to make small-molecules orally available. In fact, based on my read of what they're doing, it seems that the compounds they'll be making are less likely to be orally available than the average organic molecule pulled from the ACD. They keep adding more and more pieces to get the binding they need without regard to what it's doing to the PK/PD parameters. My guess is the molecules end up being not so small.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News